More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.74B
EPS
2.76
P/E ratio
27.9
Price to sales
7.03
Dividend yield
1.314%
Beta
0.505344
Previous close
$77.01
Today's open
$76.83
Day's range
$75.67 - $77.53
52 week range
$75.67 - $118.01
show more
CEO
George W. LeMaitre
Employees
655
Headquarters
Burlington, MA
Exchange
NASDAQ Global Market
Shares outstanding
22880871
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Dividend Champion, Contender, And Challenger Highlights: Week Of November 15
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Seeking Alpha • Nov 13, 2026

LeMaitre Vascular, Inc. (LMAT) Q3 2026 Earnings Call Transcript
LeMaitre Vascular, Inc. ( LMAT ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Dorian LeBlanc - Chief Financial Officer George LeMaitre - Chairman & CEO Conference Call Participants Michael Petusky - Barrington Research Associates, Inc., Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division James Sidoti - Sidoti & Company, LLC Michael Sarcone - Jefferies LLC, Research Division Presentation Operator Welcome to the LeMaitre Vascular Q3 2026 financial results conference call. As a reminder, today's call is being recorded.
Seeking Alpha • Nov 7, 2026

LeMaitre to Participate in Upcoming Investor Conferences
BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
GlobeNewsWire • Nov 6, 2026

LeMaitre Vascular Q3 Earnings Call Highlights
LeMaitre Vascular NASDAQ: LMAT reported 12% organic sales growth in the third quarter of 2026, driven by higher prices and unit volumes, while reiterating its full-year organic growth outlook and lowering its gross margin forecast.
MarketBeat • Nov 5, 2026

LeMaitre Q3 2026 Financial Results
BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
GlobeNewsWire • Nov 4, 2026

LeMaitre Vascular (LMAT) Misses Q3 Earnings Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.62 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Dividend Income Report: +15.25% And A Listener's Portfolio Roast
This month I tried something different on the podcast - a listener sent me one of his portfolios and asked me to roast it. He holds 29 stocks with roughly equal weight, so I built a mock $100,000 portfolio and reviewed it the way I review my own money. The current portfolio yield is 1.78%, with a 5-year dividend growth CAGR of 11.69%.
Seeking Alpha • Oct 31, 2026

LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026
BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.
GlobeNewsWire • Oct 12, 2026

LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine
LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions has improved its success rate to 80% and driven margin expansion, with gross margin rising from 65% to 72%. The company's healthy balance sheet, $376M in cash/short-term investments, and experienced management underpin its ability to pursue disciplined, accretive deals.
Seeking Alpha • Oct 1, 2026

LeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed
National class action law firm offers free, confidential case evaluations to LeMaitre Vascular investors, tenants, partners, and others whose personal information may have been exposed in the reported data breach. NEWTOWN, Pa.
PRNewsWire • Sep 24, 2026

¹ Disclosures

Open an M1 investment account to buy and sell LeMaitre Vascular Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.